Sichuan Kelun Pharmaceutical: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Sichuan Kelun Pharmaceutical: Legal Opinion of Colon Pharmaceuticals 2023 Annual General Meeting of Shareholders
Sichuan Kelun Pharmaceutical: May 13, 2024 Investor Relations Activity Schedule
Sichuan Kelun Pharmaceutical: Announcement on the results of the election of the company's employee representatives and supervisors for a new term
Sichuan Kelun Pharmaceutical: Announcement of Resolutions of the 37th Meeting of the Seventh Board of Directors
Sichuan Kelun Pharmaceutical: Announcement on the subscription for domestic shares issued by the holding subsidiary Collumbotai
Sichuan Kelun Pharmaceutical: Announcement on holding the 2023 online results briefing
Sichuan Kelun Pharmaceutical: Investor Relations Activity Schedule for April 25, 2024
Colon Pharmaceuticals: Internal Control Self-Assessment Report
Colon Pharmaceutical: Continued Supervision and Inspection Opinions and Continued Supervision Summary Report of Changjiang Securities Underwriting and Sponsorship Co., Ltd. on the spin-off of the subsidiary Yili Chuanning Biotechnology Co., Ltd. from Sichuan Colon Pharmaceutical Co., Ltd. to GEM listing
Colon Pharmaceutical: Report on the fiduciary management affairs of the public issuance of convertible corporate bonds by Sichuan Colon Pharmaceutical Co., Ltd. (2023)
Colon Pharmaceuticals: Independent Director Nominee's Statement and Commitment (Ren Shichi)
Colon Pharmaceuticals: Announcement of Supervisory Committee Resolutions
Colon Pharmaceuticals: Announcement on renewing the company's 2024 accounting firm
Colon Pharmaceuticals: First Quarter Report 2024
Colon Pharmaceuticals: Annual Verification Report on the Use of Raised Funds
Colon Pharmaceuticals: Annual Special Audit Report on Related Party Capital Occupation
Colon Pharmaceuticals: Deliberation Opinions at the 3rd Special Meeting of Independent Directors in 2024
Colon Pharmaceuticals: Shareholder Return Plan for the Next Three Years (2024-2026)
Colon Pharmaceuticals: 2023 Annual Report Summary
No Data